Impaired dopamine release in Parkinson’s disease
University of Oxford · CRUK/MRC Oxford Institute for Radiation Oncology · +2 more institutions
Abstract
Parkinson's disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlying the motor deficits in Parkinson's disease. However, decades of research suggest that dopamine release deficits in Parkinson's disease do not occur only after cell death, but that there is dysfunction or dysregulation of axonal dopamine release before cell loss. Here we review the evidence for dopamine release deficits prior to neurodegeneration in Parkinson's disease, drawn from a large and emerging range of…
Citation impact
- FWCI
- 35.09
- Percentile
- 100%
- References
- 159
Authors
4- KMKaitlyn M. L. Cramb
University of Oxford, CRUK/MRC Oxford Institute for Radiation Oncology, Science Oxford, Research Network (United States)
- DBDayne Beccano-Kelly
University of Oxford, Science Oxford
- SJStephanie J. CraggCorresponding
University of Oxford, Science Oxford, Research Network (United States)
- RWRichard Wade‐MartinsCorresponding
University of Oxford, CRUK/MRC Oxford Institute for Radiation Oncology, Science Oxford, Research Network (United States)
Topics & keywords
- Dopamine
- Parkinson's disease
- Neuroscience
- Medicine
- Dopaminergic
- Disease
- Psychology
- Internal medicine
- Good health and well-being
Funding
- MJMichael J. Fox Foundation for Parkinson's ResearchAward: ASAP-020370
- PUParkinson's UKAward: J-1403
- NSNatural Sciences and Engineering Research Council of CanadaAwards: PGSD3-517039-2018, 517039-2018, PGSD3
- MRMedical Research CouncilAwards: MR/L023784/2, MR/M024962/1, MR/P007058/1, MR/N029453/1, MR/J004324/1, MR/V013599/1, MC_EX_MR/N50192X/1, MR/K013866/1
- CFClarendon Fund